Please login to the form below

Not currently logged in
Email:
Password:

PCSK9 inhibitors

This page shows the latest PCSK9 inhibitors news and features for those working in and with pharma, biotech and healthcare.

CETP inhibitor class finally dies as Merck abandons anacetrapib

CETP inhibitor class finally dies as Merck abandons anacetrapib

The drug follows in the footsteps of other CETP inhibitors - including Pfizer's torcetrapib, Roche's dalcetrapib and Eli Lilly's evacetrapib - although those candidates all failed to show a benefit ... In the interim almost all of those brands have

Latest news

  • Merck & Co's anacetrapib data fails to generate much excitement Merck & Co's anacetrapib data fails to generate much excitement

    contend in the statin add-on market with PCSK9 inhibitors such as Amgen's Repatha, which showed a larger (15%) risk reduction in the FOURIER trial but are still struggling to ... If Merck does choose to abandon anacetrapib the drug will follow several

  • Merck & Co's anacetrapib rescued by positive phase III trial Merck & Co's anacetrapib rescued by positive phase III trial

    cholesterol-lowering drugs now that the PCSK9 inhibitors - Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab) - are being used alongside statin therapy. ... CETP inhibitors are designed to increase levels of high-density

  • Repatha outcomes data Repatha outcomes data "less than stellar"

    than stellar." Investors are now more cautious on prospects for PCSK9 inhibitors as a result, he suggested in a research note. ... It is one of only two PCSK9 inhibitors on the market, along with Sanofi and Regeneron's Praluent (alirocumab) which is also

  • Praluent can stay on market for now, says US court Praluent can stay on market for now, says US court

    Both drugs are PCSK9 inhibitors that have been approved in the US to help patients who cannot meet their cholesterol targets with existing therapy, such as statin drugs, or who have ... Praluent was approved in the US first, but Amgen has so far won the

  • Choose or lose Choose or lose

    Without evidence that they can reduce atherosclerotic plaques, Amgen and Sanofi know that PCSK9 inhibitors will struggle to get their expensive price.

More from news
Approximately 1 fully matching, plus 32 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SpotMe

SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics